Citations 24
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
Pilarski, Robert , Yurgelun, Matthew B. , Dickson, Patricia , Elkhanany, Ahmed , Friedman, Susan , Hutton, Mollie L., Khan, Seema, Klein, Catherine, Kohlmann, Wendy , Kurian, Allison W. , Laronga, Christine , Mak, Julie , Menendez, Carolyn S. , Merajver, Sofía D. , Norquist, Barbara S., Offit, Kenneth , Pederson, Holly J. , Reiser, Gwen , Shannon, Kristen M. , Visvanathan, Kala , Weitzel, Jeffrey N. , Wick, Myra , Wisinski, Kari B. , Dwyer, Mary A., Darlow, Susan, Norquist, Barbara M. , Wick, Myra J, Weitzel, Jeffrey N , Visvanathan, Kala , Kurian, Allison W , Norquist, Barbara , Elkhanany, Ahmed , Daly, Mary Beryl , Berry, Michael P., Buys, Saundra S. , Domchek, Susan M. , Garber, Judy E. , Goggins, Michael , Litton, Jennifer K. , Pal, Tuya
Journal of the National Comprehensive Cancer Network | April 7, 2020 | Volume: 18 | Issue: 4 | Pages: 380-391
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2 , pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Michaelson, M. Dror , Nandagopal, Lakshminarayanan , George, Saby , Alva, Ajjai , Harrison, Michael R. , Sosman, Jeffrey A. , Bhayani, Sam B., Choueiri, Toni K. , Costello, Brian A. , Derweesh, Ithaar , Kyriakopoulos, Christos E. , LaGrange, Chad A. , Lau, Clayton, Lewis, Bryan , McCreery, Brittany, McDonald, Andrew , Mortazavi, Amir , Ponsky, Lee , Redman, Bruce G., Somer, Bradley G. , Wile, Geoffrey, Dwyer, Mary A., CGC, Hammond, Lydia J., Zuccarino-Catania, Griselda, Choueiri, Toni K , Motzer, Robert J. , Jonasch, Eric W. , Gore, John L. , Haas, Naomi B , Plimack, Elizabeth R. , Agarwal, Neeraj , Gallagher, Thomas H. , Hancock, Steven Lee , Lam, Elaine T. , Manley, Brandon J. , Pierorazio, Phillip , CGC
Journal of the National Comprehensive Cancer Network | November 7, 2019 | Volume: 17 | Issue: 11 | Pages: 1278-1285
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
Advani, Ranjana H. , Bartlett, Nancy L. , Chang, Julie , Christian, Beth , Fayad, Luis , Glenn, Martha, Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Khan, Nadia , Krivacic, Susan, LaCasce, Ann S. , Nademanee, Auayporn, Rabinovitch, Rachel , Reddy, Nishitha , Roberts, Kenneth B. , Smith, Stephen D. , Swinnen, Lode J., Dwyer, Mary A., Sundar, Hema, Bartlett, Nancy L , Advani, Ranjana H , Khan, Nadia , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Caimi, Paolo F. , Chavez, Julio C , Habermann, Thomas M. , Harris, Nancy L. , Kelsey, Chris R. , Mehta, Amitkumar , Reid, Erin G , Snyder, Erin Dunn , Vose, Julie M.
Journal of the National Comprehensive Cancer Network | June 17, 2019 | Volume: 17 | Issue: 6 | Pages: 650-661
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin’s lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
AIDS-Related Kaposi Sarcoma, Version 2.2019
Suneja, Gita , Ambinder, Richard F. , Ard, Kevin L. , Baiocchi, Robert A. , Cohen, Adam K. , Crysler, Oxana , Gupta, Neel K. , Gustafson, Chelsea, Hall, Andre, Johung, Kimberly L. , LaCasce, Ann S. , Lin, Chi , Menon, Manoj , Morgan, David , Nathwani, Nitya , Ratner, Lee , Rizza, Stacey A. , Sanchez, Julian , Taylor, Jeff , Tomlinson, Benjamin , Wang, Chia-Ching J., Dwyer, Mary A., CGC, Freedman-Cass, Deborah A., Rizza, Stacey , Ratner, Lee , Reid, Erin G , Barta, Stefan K , Carchman, Evie H. , Klopp, Ann H. , Mehta, Amitkumar , Noy, Ariela , Rudek, Michelle A. , Yendamuri, Sai S , CGC, Freedman-Cass, Deborah A., Ambinder, Richard F
Journal of the National Comprehensive Cancer Network | February 20, 2019 | Volume: 17 | Issue: 2 | Pages: 171-189
As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.